32 Questions 55 Answers 0 Followers
Questions related from Peter Kubisz
Dear colleagues, What is your experience in off-label use of low-dose (50-70 µg/kg) recombinant factor VIIa? Especially in surgical patients with underlying malignancy and life-threatining...
15 August 2016 4,746 1 View
Have you encountered such combination of rare bleeding disorders (RBD)? We recently consulted female undergoing hysterectomy, diagnosed with vWF type I disease , with supposed antithrombin...
01 June 2016 8,651 2 View
What do you think about utility of platelet rich plasma (PRP) in treatment of tendon and ligament injuries? What is your experience with this method and your preferred preparation methods. Would...
01 June 2016 1,220 6 View
What do you think about immunogenicity of new long lasting recombinant coagulation factor concentrates (CFCs)? Do you have any experience? In your practice, what difference do you observe in...
01 June 2016 2,889 1 View
How do you manage patients with afibrinogenemia? Do you prefer prophylactic or on demand treatment? What doses and what are your fibrinogen target levels? Also, how do you prevent thromboembolic...
23 May 2016 3,465 2 View
What is your practical experience with SPS and fetal loss and deep vein thrombosis?
18 March 2016 2,769 4 View
What is your experience and strategy in treatment of Hemophilia B in PUPs and PTPs. Regards Peter
18 March 2016 8,588 3 View
What is Your opinion on incidence of inhibitor formation in patients treated by plasma derived versus recombinant clotting factor concentrates? What is your current practical approach in choosing...
08 March 2016 393 1 View
What is Your experience with sticky platelet syndrome (SPS) ? SPS, characterized by platelet hyperaggregability has been identified as cause of 21% cases of unexplained arterial and 13,2% of...
08 March 2016 4,191 5 View
What is Your experience with ITI in plasma derived (PD) and recombinant concentrates? Besides economical aspects, what are your results in comparison between used preparate? What is...
08 March 2016 1,517 1 View
Do You think mutation as described above (C-T transversion leading to premature stop codon) can cause almost complete lack of fibrinogen in patient? Do you have experienci with patients with...
08 March 2016 3,176 4 View
What type of preparate do You consider better in terms of formation of inhibitor?
04 January 2016 3,455 3 View
Considering the amount of von Willebrand factor in PDF VIII , what type of PDF composition (amount of vWF) is better for ITI in Hemophilia A?
04 January 2016 8,750 1 View
Dear Colleagues, What is Your approach in laboratory monitoring of patients on Dabigatran treatment? What is Your experience with HEMOCLOT assay, or another assay?
04 January 2016 4,618 4 View
What drug in Your experience has the best outcome in treatment along with most convenient economic burden?
04 January 2016 5,248 3 View
59-year old female patient with Von Willebrand disease type I (on demand treatment ) and squamous-cell carcinoma in facial area, currently without initiated chemotherapy. Patient is scheduled for...
30 September 2015 9,801 5 View
Dear colleague, By the way did you accidentally see haemophilia patients with HCV infection and haematological malignancy?
04 February 2015 8,936 3 View
Congratulations, you discussed a very interesting issue. I agree with the individualized therapeutic approach, especially in the patients with mild haemophilia phenotype. I would like to discuss...
30 January 2015 1,817 6 View
We would like to clarify the possible role of dendritic cells in process of coagulation. Do you believe in it? Dendritic cells are derived from hematopoietic progenitor cells and may play a role...
21 August 2014 4,741 3 View
Can haemophilia with inhibitor be treated with different products within one immunotolerance treatment? Can we change the main product during the course of treatment? Do you have any experience...
21 August 2014 5,609 3 View
Diagnosis of inherited thrombocytopathy
21 August 2014 9,942 4 View
Do you use a more convenient and more straightforward method to separate leukocytes in flow cytometric determination of anti-leukocyte antibodies? In our practice, we use phycol-verographine...
24 March 2014 5,367 1 View
Do You analyze concentration of CD 133+/34- endothelial progenitor cells in the bone marrow and in stem cell products before administration in the critically ischemic limb of the patients with...
16 December 2013 9,535 1 View
Stem cells viability assessment in the therapeutic angiogenesis for CLI.
16 December 2013 8,016 2 View
What do you think about the use of ASA in secondary prevention of cardioembolic ischemic stroke in some cases (e.g. SPS ref. Semin Thromb Hemost. 2013 Sep;39(6):674-83.) Some guidelines recommend...
29 November 2013 8,695 2 View
1) Is luminescence method currently the most sensitive method for the analysis of vWF multimers? 2) Is there software to determine the molecular weight of vWF multimers evaluated by densitometry?
29 November 2013 10,046 1 View
Are the multimers of von Willebrand factor important for the confirmation of the diagnosis of certain vWD subtypes? What is your experience with their assessment? Can you recommend your farourite...
27 September 2013 6,944 3 View
Is there an association between SPS phenotype and genetic abnormalities?
16 September 2013 6,633 0 View
Platelet hyperaggregability in connection with pregnancy loss is well known, but is there a relationship to certain platelet membrane protein gene polymorphisms?
11 September 2013 1,252 0 View
Do you know something about the impact of sticky platelet syndrome subtypes on deep vein thrombosis?
11 September 2013 3,495 8 View
I am interested in gene association studies related to the platelet hyperaggregability and both venous and arterial thrombosis.
22 August 2013 7,641 12 View
Immune tolerance induction has been accepted as the only clinically proven treatment allowing antigen-specific tolerance to factor VIII. However, some of its issues, such as patient selection,...
22 August 2013 2,728 1 View
